Orbex Expands Its Offering with
11 New Cryptocurrency Pairs

As part of our ongoing commitment to offer clients the best selection of trading instruments, we are pleased to announce that we have recently introduced a new cryptocurrency CFD offering featuring 11 of the world’s most popular cryptocurrencies. Our new cryptocurrency range comes amid increasing demand for online crypto trading and spans the most prominent coins by market capitalization including Bitcoin, Ethereum, Litecoin, Bitcoin Cash, Ripple, Cardano, Dogecoin, Polkadot, EOS, Chainlink and Stellar.

The newly listed cryptocurrencies are all pegged against the US dollar and can be traded on a 24-hour basis on any Orbex MetaTrader 4 platform. Our cryptocurrency CFDs afford traders the opportunity to trade bith rising and falling crypto prices and realize a P&L when their trades are closed, without having to buy or store digital currencies in a wallet. When trading cryptocurrencies, Orbex traders can also benefit from our array of exclusive charting tools, advanced and flexible trade sizes. Our crypto trading costs are set at just 0.5% commission per trade, and with a 50% margin requirement, our crypto traders are able to double their positions with 1:2 leverage.

The introduction of our new crypto range adds to our rapidly expanding suite of tradable assets which currently features some of the world’s most popular markets including forex, equities, indices, metals, energies and futures. Orbex’s Chairman Abdullah Abbas has commented on the news:

“Delivering on our promise of providing our clients access to a wide range of markets at the best possible trading conditions, we are very pleased to announce the launch of our new cryptocurrency offering. Orbex clients can now diversify their portfolio with some of the world’s leading cryptocurrencies, available to trade with CFDs 24/5. At Orbex, we remain committed to keeping pace with market trends and gauging investor demand in order to continue to innovate with new assets, tools, and services for our clients.”